Icotinib
-
Catalog numberB3003-25
-
PricePlease ask
-
Size25 mg
-
-
Alternative_nameBPI-2009; BPI-2009H; N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine; Conmana; (3-Ethynyl-phenyl)(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diazacyclododeca[b]naphthalen-4-yl)-amine; N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine
-
DescriptionIcotininb is a potent epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC₅₀ of 5 nM. It blocks EGFR-mediated intracellular tyrosine phosphorylation IC₅₀ of 45 nM in the human epidermoid carcinoma A431 cell line and inhibits tumor cell proliferation. Icotinib shows potent dose-dependent antitumor effects in nude mice carrying a variety of human tumor-derived xenografts. The drug is well tolerated at doses up to 120 mg/kg/day in mice without mortality or significant body weight loss during the treatment.
-
CAS Number610798-31-7
-
Structure Available1
-
Molecular FormulaC₂₂H₂₁N₃O₄
-
Molecular Weight391.4
-
Cell Permeable1
-
Purity>99%
-
Solubilities~75 mg/ml in DMSO
-
HandlingDo not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.
-
Tag LineA potent EGFR inhibitor
-
Storage Condition-20ºC
-
Shipping ConditionRT
-
Shelf Life36 months
-
MDL NumberMFCD22124501
-
PubChem CID22024915
-
SMILESC#CC1=CC(=CC=C1)NC2=NC=NC3=CC4=C(C=C32)OCCOCCOCCO4
-
InChiInChI=1S/C22H21N3O4/c1-2-16-4-3-5-17(12-16)25-22-18-13-20-21(14-19(18)23-15-24-22)29-11-9-27-7-6-26-8-10-28-20/h1,3-5,12-15H,6-11H2,(H,23,24,25)
-
InChi KeyQQLKULDARVNMAL-UHFFFAOYSA-N
-
MSDS Available1
-
Gene target
-
Short nameIcotinib
-
Alternative nameIcotinib
-